Foresee Pharmaceuticals
Manufacturing · Taiwan · 51-200 Employees
View Company Info for Free
Overview
Headquarters
no. 19-3 Sanchong Rd 9th FLOOR2, Taipei,...Phone Number
+886 277500188Website
www.foreseepharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Foresee Pharmaceuticals
Foresee Pharmaceuticals Co., Ltd. (FP) is a clinical-stage pharmaceutical company. The company's mission is to serve patients. The company strives to improve patients' quality of life and provide cure through innovative research. The company is committed to apply the highest ethical standards to the company's products, services and communications. Foresee's core competency includes rapid development and commercialization of new drugs using its proprietary drug delivery technology as well as develop first-in-class NCE in disease areas of high unmet medical needs.Explore more
Foresee Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Foresee Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Foresee Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Foresee Pharmaceuticals had a recent Job posting/layoffs
Check out if Foresee Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Foresee Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Foresee Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Foresee Pharmaceuticals
Foresee Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Foresee Pharmaceuticals has new funding data
Recommended Actions
Find VP level buyers at Foresee Pharmaceuticals
Find 2 more new buyers
Company Profile Activity
Activity Insights
Foresee Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Foresee Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Foresee Pharmaceuticals.
Foresee Pharmaceuticals financials insights
Gather financial insights about Foresee Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$47M
2023
Share Placement
$42.3M
Foresee Pharmaceuticals Tech Stack
A closer look at the technologies used by Foresee Pharmaceuticals
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Event
Events
Open Position
Funding
Foresee Pharmaceuticals News & Media
Foresee's Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2a Platform Trial
TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in Parkinson's disease in the SLEIPNIR Phase 2a platform trial, in collaboration with...Foresee Pharmaceuticals Announces Completion of Casppian Phase 3 Study with Last Patient Last Visit and Confirms Topline Results: 94% of Patients Achieve LH Suppression with 6-Month Dosing Interval of Leuprolide Mesylate, also the acceptance of Casppian Study for Presentation at Endocrine Society, ENDO 2026 Medical Conference, as a Potential New Six-Month Treatment Option for Central Precocious Puberty
Foresee outlines plan for NDA submission to FDA and other global health authorities by late 2026 Plan for NDA Submission and Global Regulatory Filings The Casppian Phase 3 Study was accepted for Presentation at the Endocrine Society, ENDO 2026: A Potential New Six-Month Treatment Option...Foresee Pharmaceuticals Welcomes Positive CHMP Opinion Recommending Approval of CAMCEVI 21mg, 3-month strength in the European Union for Advanced Prostate Cancer
TAIPEI, March 6, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced that it has received notification from its licensing partner, Accord Healthcare, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a...Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP)
The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of the study as planned. The Casppian study design included periodic evaluations and long-term safety monitoring for up to a total of 12 months following the first injection. There has been no safety...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Foresee Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Foresee Pharmaceuticals Co., Ltd. (FP) is a clinical-stage pharmaceutical company. The company's mission is to serve patients. The company strives to improve patients' quality of life and provide cure through innovative research. The company is committed to apply the highest ethical standards to the company's products, services and communications.... Read More
